HBMN:SWX
HBM Healthcare Investments AG
232,00 CHF
arrow_upward
+0,87%(+2,00) 1 D
29. apr., 09:42:23 GMT+2 · CHF
search
Alle symboler
1 D
5 D
1 M
6 M
I år
1 Å
5 Å
MAKS
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for HBMN …
Åpne
233,50 CHF
Høy
233,50 CHF
Lav
232,00 CHF
Markedsverdi
1,57 mrd.
Snittvolum
6,47k
Volum
71,00
Utbytte
3,23 %
Kvartalsvis utbytte
1,87 CHF
Første dato etter utbytte
2. juli 2025
P/E-forhold
6,46
52 u høy
245,50 CHF
52 u lav
157,40 CHF
EPS
35,93 CHF
Utestående aksjer
6,74 mill.
Nyhetssaker
Fra kilder på nettet
Seeking Alpha
·
for 13 minutter siden
Nasdaq 100: AI Bubble Fears Overblown, Bullish Trend Intact Above 26,760 Key Intraday Support
MarketBeat
·
for 14 minutter siden
Cadiz (NASDAQ:CDZI) Stock Price Passes Below 200-Day Moving Average - Time to Sell?
Simply Wall Street
·
for 19 minutter siden
Do Elevate Solutions And Motivosity Integration Reveal A Deeper Shift In Paylocity’s (PCTY) Strategy?
MarketBeat
·
for 58 minutter siden
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Om HBM Healthcare Investments AG
Administrerende direktør-
Ansatte-
Grunnlagt12. juli 2001
HovedkontorZug, Zug, Sveits
Sektor-
Nettstedhbmhealthcare.com
AI-innhold kan inneholde feil. Finn ut mer